Table II.

NOD-IL-4 splenocytes inhibit the development of insulitis^a

Group	Donor Splenocytes From	Recipients	Total No. of Islets/Group	Grade of Insulitis (%)				Insulitis Score
Group	Donor Splenocytes From	Recipients	Total No. of Islets/Group	0	1	2	3	Insulitis Score
A	Diabetic	NOD	77	12	39	26	23	1.6
	Diabetic	NOD-IL-4	48	65	29	6	0	0.41^b

B	GAD65-stimulated	NOD	75	15	12	32	41	2.0
	GAD65-stimulated	NOD-IL-4	89	69	19	11	1	0.45^b

C	Diabetic+ NOD	NOD.scid	48	15	29	45	11	1.5
	Diabetic+ NOD-IL-4	NOD-scid	88	48	33	19	0	0.71**

D	GAD65-stimulated-NOD+ diabetic	NOD.scid	41	18	24	35	23	1.6
	GAD65-stimulated-NOD-IL-4+ diabetic	NOD.scid	47	69	19	13	0	0.45**

a Pancreatic islets were scored for insulitis by hematoxylin and eosin staining 7 days following adoptive transfer of 5 × 10⁶ recently diabetic NOD splenocytes (group A); 1.5 × 10⁷ GAD65 stimulated NOD splenocytes (group B); 3 × 10⁶ diabetic plus 1.5 × 10⁷ NOD or NOD-IL-4 (group C); or 1 × 10⁷ GAD65 stimulated plus 5 × 10⁶ recently diabetic NOD splenocytes (group D).
b p < 0.0001; ** p < 0.01 (χ² test).